Beam reveals what tripped up its base-edited, off-the-shelf CAR-T as it tries to clear FDA hold

Max Gelman

Senior Editor

Last month, Beam Therapeutics revealed the FDA intended to place its preclinical off-the-shelf CAR-T therapy on hold. Today, the company revealed the reasons why. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Beam reveals what tripped up its base-edited, off-the-shelf CAR-T as it tries to clear FDA hold

Max Gelman

Senior Editor

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases

Beam re­veals what tripped up its base-edit­ed, off-the-shelf CAR-T as it tries to clear FDA hold

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

Beam reveals what tripped up its base-edited, off-the-shelf CAR-T as it tries to clear FDA hold

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases